Table 2 |
|||||
|
Prescribing rates for CHD drugs |
|||||
| Drug |
Star-PUs |
||||
|
|
|||||
| Cases |
Controls |
Difference [95% C.I.] |
% Difference |
||
|
|
|||||
| Unmatched |
Matched |
||||
|
|
|||||
| Statins* (BNF Chapter 2, 2.12) |
98.9 |
99.4 |
136.7 |
-37.8 [-66.7 to -11.5] |
-27.7% |
| Ace Inhibitors (BNF Chapter 2, 2.5.5) |
104.7 |
97.3 |
144.4 |
-39.7 [-64.3 to -14.5] |
-27.5% |
| Amlodipine BNF Chapter 2, 2.6) |
89.2 |
107.0 |
102.2 |
-13.0 [-44.3 to 13.4] |
-12.8% |
| Beta blockers (BNF Chapter 2, 2.4) |
92.7 |
101.9 |
106.2 |
-13.5 [-38.9 to 9.9] |
-12.7% |
| Clopidogrel (BNF Chapter 2, 2.9) |
86.6 |
99.6 |
154.3 |
-67.6 [-105.8 to -17.8] |
-43.9% |
| Thiazide ((BNF Chapter 2, 2.5) |
92.7 |
103.4 |
134.8 |
-42.2 [-62.7 to -23.6] |
-31.3% |
| Aspirin (BNF Chapter 2, 2.9) |
109.0 |
102.2 |
136.2 |
-27.2 [-57.7 to 3.6] |
-20% |
| Warfarin (BNF Chapter 2, 2.8) |
77.2 |
100.2 |
101.7 |
-24.5 [-38.1 to -6.5] |
-24.1% |
| Spironolactone (BNF Chapter 2, 2.5) |
87.0 |
100.3 |
109.8 |
-22.9 [-63.9 to 0.6] |
-20.8% |
| Digoxin (BNF Chapter 2, 2.1) |
92.0 |
100.9 |
122.6 |
-30.6 [-55.7 to -9.6] |
-25% |
|
|
|||||
|
Notes: * measured in Defined Daily Doses |
|||||
|
McLean International Journal for Equity in Health 2008 7:18 doi:10.1186/1475-9276-7-18 |
|||||
